

## 1 **Breakthrough SARS-CoV-2 infections in MS patients on disease modifying therapies**

2 Irene Schiavetti<sup>1</sup>, Cinzia Cordioli<sup>2</sup>, Maria Laura Stromillo<sup>3</sup>, Maria Teresa Ferrò<sup>4</sup>, Alice Laroni<sup>5,6</sup>, Eleonora  
3 Cocco<sup>7</sup>, Gaia Cola<sup>8</sup>, Livia Pasquali<sup>9</sup>, Maria Teresa Rilla<sup>10</sup>, Elisabetta Signoriello<sup>11</sup>, Rosa Iodice<sup>12</sup>, Alessia Di  
4 Sapio<sup>13</sup>, Roberta Lanzillo<sup>14</sup>, Francesca Caleri<sup>15</sup>, Pietro Annovazzi<sup>16</sup>, Antonella Conte<sup>17,18</sup>, Giuseppe  
5 Liberatore<sup>19</sup>, Francesca Ruscica<sup>20</sup>, Renato Docimo<sup>21</sup>, Simona Bonavita<sup>22</sup> Monica Ulivelli<sup>23</sup>, Paola Cavalla<sup>24</sup>,  
6 Francesco Patti<sup>25</sup>, Diana Ferraro<sup>26</sup>, Marinella Clerico<sup>27</sup>, Paolo Immovilli<sup>28</sup>, Massimiliano Di Filippo<sup>29</sup>, Marco  
7 Salvetti<sup>30,18</sup>, Maria Pia Sormani<sup>1,5</sup> and the “Breakthrough infections in MS” study group

8

- 9 1. Department of Health Sciences, Section of Biostatistics, University of Genova, Italy  
10 2. Centro Sclerosi Multipla ASST Spedali Civili di Brescia  
11 3. Clinica Neurologica e Malattie Neurometaboliche, Università degli Studi di Siena  
12 4. Neuroimmunology, Center for Multiple Sclerosis, Cardiocerebrovascular Department, Neurological Unit,  
13 ASST Crema  
14 5. IRCCS Ospedale Policlinico San Martino, Genova, Italy  
15 6. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health,  
16 University of Genova, Italy  
17 7. Centro Sclerosi Multipla Ospedale Binaghi Cagliari  
18 8. "Department of Systems Medicine, Multiple Sclerosis Clinical and Research Unit, Tor Vergata, University,  
19 Rome, Italy"  
20 9. Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa, Italy  
21 10. Department of Neurology, Imperia Hospital, Imperia, Italy  
22 11. II Division of Neurology, University of Campania Luigi Vanvitelli  
23 12. Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico  
24 II", Naples, Italy  
25 13. Department of Neurology, Regina Montis Regalis Hospital, Mondovì, Italy  
26 14. Federico II University of Naples  
27 15. Department of Neurology, MS Center, F. Tappeiner Hospital Meran (BZ), Italy  
28 16. UOC Centro Sclerosi Multipla, ASST Valle-Olona, PO di Gallarate (VA)  
29 17. Department of Human Neuroscience, Sapienza, University of Rome, Italy.  
30 18. IRCCS Neuromed, Pozzilli (IS), Italy  
31 19. Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy  
32 20. U.O.C. Neurologia e Centro SM - Fondazione Istituto G. Giglio, Cefalù (Italy)  
33 21. Multiple Sclerosis Center, Aversa Hospital "San Giuseppe Moscati", ASL Caserta, Aversa (Ce) Italy  
34 22. Dipartimento di Scienze Mediche e Chirurgiche avanzate, Università della Campania Luigi Vanvitelli, Naples-  
35 Italy  
36 23. Department of Medical Sciences, Surgery and Neurosciences, University of Siena  
37 24. Multiple Sclerosis Center and 1st Division of Neurology, Department of Neuroscience, City of Health and  
38 Science University Hospital of Turin, Italy

- 39 25. Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of  
40 Catania, Catania, Italy.
- 41 26. Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena,  
42 Italy.
- 43 27. Clinical and Biological Sciences Department, University of Torino
- 44 28. Guglielmo da Saliceto Hospital, Piacenza
- 45 29. Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy
- 46 30. Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy

47

48 Corresponding author: **Maria Pia Sormani**, Department of Health Sciences, Via Pastore 1, 16132,  
49 University of Genova, Italy

50 Email: [mariapia.sormani@unige.it](mailto:mariapia.sormani@unige.it)

51 Tel: +39-3669937472

52

53 Keywords: Multiple Sclerosis, Covid-19 vaccination, Breakthrough infections

54 Number of characters in the title: 80

55 Number of words: 1394

56 Number of figures: 1

57 Number of tables: 1

58 Number of references: 11

59

60 **Abstract**

61 **Background.** Patients with Multiple Sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a  
62 reduced humoral response to SARS-CoV-2 vaccines. In this study we aimed to monitor the risk of  
63 breakthrough SARS-CoV-2 infection in pwMS on different Disease Modifying Therapy (DMT).

64 **Methods.** Data on number of vaccinated patients and of patients with a breakthrough infection were  
65 retrospectively collected in 27 Italian MS centers. We estimated the rate of breakthrough infections and of  
66 infection requiring hospitalization per DMT.

67 **Findings.** 19641 vaccinated pwMS were included in the database. After a median follow-up of 8 months, we  
68 observed 137 breakthrough infections. As compared to the other DMTs, the rate of breakthrough infections  
69 was significantly higher on ocrelizumab (0.57% vs 2.00%, RR=3.55,95%CI=2.74-4.58, p<0.001) and  
70 fingolimod (0.58% vs 1.62%, RR=2.65,95%CI=1.75-4.00, p<0.001), while there were no significant  
71 differences in any other DMT group. In the ocrelizumab group the hospitalization rate was 16.7% vs 19.4%  
72 in the pre-vaccination era (RR=0.86,p=0.74) and it was 3.9% in all the other DMT groups vs 11.9% in the  
73 pre-vaccination period (RR=0.33,p=0.02).

74 **Interpretation.** The risk of breakthrough SARS-CoV-2 infections is higher in patients treated with  
75 ocrelizumab and fingolimod, and the rate of severe infections was significantly reduced in all the DMTs  
76 excluding ocrelizumab.

77

## 78 **Introduction**

79 Several recent studies evaluated the effect of vaccination against SARS-CoV-2 in patients with multiple  
80 sclerosis (pwMS) treated with disease-modifying therapies (DMTs). There is wide consensus that the use of  
81 anti-CD20 monoclonal antibodies and fingolimod are associated with an impaired virus-specific humoral  
82 immune response as compared to all the other DMTs<sup>1-4</sup>. On the other hand, there is also growing evidence  
83 that vaccinated pwMS treated with anti-CD20 generated robust virus specific CD4 and CD8 T cell  
84 responses<sup>4-5</sup>, while these are slightly reduced in fingolimod treated patients<sup>5</sup>. A preliminary follow-up study  
85 of 344 fully vaccinated pwMS on DMT reported 13 breakthrough infections, 10 of which were in patients on  
86 anti-CD20 therapy and the remaining 3 on fingolimod<sup>6</sup>, suggesting a relevant role of antibodies in preventing  
87 the infection. The French registry recently reported a case series of 18 pwMS who had Covid-19 after two  
88 doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod<sup>7</sup>. Finally, the  
89 clinical follow up of the CovXiMS study<sup>1</sup> evaluating humoral response in 1705 pwMS who received two  
90 doses of mRNA vaccines<sup>8</sup>, reported 23 breakthrough infections over a 6 month follow up. The risk of  
91 infection was associated with lower SARS-CoV-2 antibody levels measured after 4 weeks from the second  
92 vaccine dose<sup>8</sup>.

93 Against this background and taking advantage of the large network of MS centers within the Italian Alliance  
94 against Covid-19 promoted by the Italian MS Society, we collected data from 27 Italian MS centers on the  
95 number of vaccinated patients and the number of patients who had a breakthrough infection in each DMT  
96 group, in the period preceding the spread of the Omicron variant, that started its massive diffusion in Italy  
97 after the December 2021 holiday season. Aim of this study is to estimate the rate of breakthrough infections  
98 per DMT class on a large sample of vaccinated pwMS and to compare the rates of severe infections to the  
99 rate observed in Italy in the pre-vaccination era<sup>9</sup>.

100

## 101 **Patients and Methods**

102 *Study design and participants*

103 This was a retrospective data collection conducted in 27 Italian MS centers on pwMS undergoing the SARS-  
104 CoV-2 vaccination. Each MS center was requested to report the number of pwMS vaccinated by two mRNA  
105 vaccine doses (BNT162b2 (Pfizer Inc, and BioNTech), or mRNA-1273 (Moderna Tx, Inc)) in each DMT  
106 group from March 2021 to December 25, 2021. Data cutoff was set before the spread of the Omicron variant  
107 in Italy, since on December 23, 2021 the percentage of Omicron infections was estimated to be 28%  
108 (<https://www.iss.it/primo-piano>, accessed on December 25, 2021). Breakthrough infections occurred within  
109 8 months, defined as a PCR-confirmed test after 14 days from the second or the third vaccine dose, were  
110 extracted from the platform dedicated to Covid-19 data collection in pwMS (MuSC-19 database<sup>10</sup>) for the  
111 participating centers. The post-vaccination SARS-CoV-2 infection was recorded in a dedicated Case Report  
112 Form (CRF).

113 The study is done in compliance with the principles of the Declaration of Helsinki. The study was approved  
114 by the regional ethics committee of Liguria (University of Genoa; n 130/2020–DB id 10433) and at a  
115 national level by the Italian Medicines Agency. Written informed consent was obtained from all participants  
116 before starting any study procedures.

#### 117 *Primary Outcome: breakthrough infection*

118 The primary objective of this analysis was to compare the incidence of breakthrough SARS-CoV-2  
119 infections among the vaccinated pwMS in each DMT group. These conditions entail a PCR-confirmed  
120 swab, and a time lag of at least 14 days from a full vaccination cycle (after the second or third vaccination  
121 dose, or after the first dose following a Covid-19 infection).

#### 122 *Statistical analysis*

123 The percentage of patients with a breakthrough infection in the different DMT groups was calculated. 95%  
124 Confidence Intervals (CI) were estimated using the normal approximation to the binomial calculation<sup>11</sup>.  
125 Difference of rate of infections between DMT groups were estimated by Risk Ratios (RR) and evaluated by  
126 Chi-square tests. Difference of rate of infections in the first 4 months vs the second 4 months of follow up  
127 were estimated by ORs and evaluated by the McNamar test for paired data.

#### 128 *Funding*

129 FISM [2021/Special-Multi/001].

130

## 131 **Results**

132 Data were collected between March 1, 2021 and December 24, 2021. 19641 pwMS who had a full  
133 vaccination cycle with an mRNA vaccine (2 or 3 vaccine dose, or 1 vaccine dose after Covid-19 infection)  
134 were included in the database. The number of vaccinated pwMS in each DMT group is reported in Table 1.  
135 The mean follow-up time was 249 days (range 99-354). Among them, 137 breakthrough infections were  
136 observed (26 (19.0%) after the third dose, 1 after Covid-19 infection and one dose) over a mean interval after  
137 the last vaccine dose of 142 days (range 14-262) (Table 1). Over the whole follow-up of about 8 months, we  
138 compared the proportion of patients with breakthrough infections in each DMT group to the pooled  
139 proportion of the patients on all the other DMTs (Figure 1, panel A). The rate of breakthrough infections  
140 was significantly higher in patients treated with ocrelizumab (2.00%, 95%CI=1.36-2.66) than in patients  
141 treated with all the other DMTs (0.57%, 95%CI=0.46%-0.68%) with a RR=3.55, 95%CI=2.74-4.58,  
142  $p<0.001$ ; the same was observed in patients treated with fingolimod who had a higher rate of breakthrough  
143 infections (1.62%, 95%CI= 1.02%-2.21%) than the patients treated with all the other DMTs (0.61%,  
144 95%CI=0.50-0.72) with a RR=2.65, 95%CI= 1.75-4.00,  $p<0.001$ . Among the patients who had the SARS-  
145 CoV-2 infection, 10 (7.3%) had a severe disease course and were hospitalized. Six patients treated with  
146 ocrelizumab were hospitalized and in this group the rate of hospitalization was 16.7%, slightly lower but not  
147 significantly different than the pre-vaccination rate observed in Italy (19.4%) in the same DMT group<sup>7</sup>  
148 (relative reduction=14%, RR=0.86, 95%CI=0.38-1.91,  $p=0.74$ ). In the fingolimod group we observed just 1  
149 hospitalized patient (3.6%). The rate of hospitalization was 3.9% in all the other DMT groups as compared to  
150 11.9% in the pre-vaccination period<sup>7</sup> (relative reduction=67%, RR=0.33, 95%CI=0.13-0.88,  $p=0.02$ ). One  
151 patient in ocrelizumab was admitted to the Intensive Care Unit (ICU) and recovered.

152 Figure1, panel B, reports the rate of breakthrough infections in two time periods of equal duration: the first 4  
153 months following the last vaccination dose vs the period 4-8 months after the last vaccination dose in  
154 patients treated with ocrelizumab, fingolimod and all the other DMTs. The rate in patients treated with

155 ocrelizumab and fingolimod was not significantly affected by the time since vaccination (ocrelizumab: 0-4  
156 months after vaccination: 0.84%, 4-8 months after vaccination: 1.18%, OR=1.40, p=0.31; fingolimod: 0-4  
157 months after vaccination: 0.86%, 4-8 months after vaccination: 0.76%, OR=0.88, p=0.75). In all the other  
158 DMT groups the rate is much lower (0-4 months after vaccination: 0.14%) and it was significantly increased  
159 after 4 months from the last vaccine dose (4-8 months after vaccination: 0.32%, OR=2.32, 95% CI=1.38-  
160 4.01, p<0.001).

## 161 **Discussion**

162 This study on a large sample of pwMS who received a full vaccination cycle confirms that the risk of  
163 contracting SARS-CoV-2 infection after Covid-19 m-RNA vaccines is higher in pwMS on anti-CD20  
164 monoclonal antibodies or fingolimod. We observed just one admission to ICU and no deaths. Despite the  
165 small sample of 137 infections, two results emerge. First, in our cohort, among the infected patients after  
166 vaccination treated with ocrelizumab the hospitalization rate is very similar to the hospitalization rate of  
167 patients on the same treatment in the pre-vaccination era<sup>8</sup>, while it is reduced by 67% in pwMS in other  
168 DMTs. However, we must consider that this result can be confounded by an increased propensity of clinician  
169 to admit to hospital pwMS on ocrelizumab who develop Covid-19, because of previous studies showing that  
170 these patients are at a higher risk for a severe course<sup>8</sup>. Second, as expected<sup>9</sup>, the vaccine-induced protection  
171 from the disease is waning with time since vaccination, and this is more evident in patients treated with  
172 DMTs other than ocrelizumab and fingolimod, who already had low antibody levels soon after the  
173 vaccination. In fact, while the infection rate is similar in the first and in the second four months after  
174 vaccination in patients on ocrelizumab and fingolimod, and consistently higher than in patients on other  
175 DMTs, the initial protective effect is vanishing with time for patients in the other DMTs group, who had a  
176 good level of antibody response four weeks after vaccination<sup>1</sup>. This study complements the information of  
177 previous studies reporting the antibody levels after anti-SARS-Cov-2 vaccination in pwMS on different  
178 DMTs<sup>1-7</sup>, suggesting that antibodies play a dominant role in preventing Covid-19 infections and their severe  
179 consequences.

180

181 **References**

- 182 1. Sormani MP, Inglese M, Schiavetti I et al. Effect of SARS-CoV-2 mRNA vaccination in MS  
183 patients treated with disease modifying therapies. *EBioMedicine*. 2021 Oct;72:103581. doi:  
184 10.1016/j.ebiom.2021.103581.
- 185 2. Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA  
186 vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.  
187 *Ther Adv Neurol Disord*. 2021. doi:10.1177/17562864211012835
- 188 3. Tallantyre EC, Vickaryous N, Anderson V et al. COVID-19 Vaccine Response in People with  
189 Multiple Sclerosis. *Ann Neurol* 2021; Oct 22. doi: 10.1002/ana.26251. Online ahead of print
- 190 4. Tortorella C, Aiello A, Gasperini C et al. Humoral- and T-Cell-Specific Immune Responses to  
191 SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying  
192 Therapies. *Neurology* in press
- 193 5. Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following  
194 SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med*.  
195 2021 Nov;27(11):1990-2001. doi: 10.1038/s41591-021-01507-2.
- 196 6. Rose DR, Mahadeem AZ, Carlson AK et al. Clinical features and outcomes of COVID-19 despite  
197 SARS-CoV-2 vaccination in people with multiple sclerosis. *Mult Scler J Exp Transl Clin*. 2021 Nov  
198 26;7(4):20552173211057110. doi: 10.1177/20552173211057110. eCollection 2021 Oct.
- 199 7. Januel E , De Seze J, Vermersch P et al. Post-vaccine COVID-19 in patients with multiple sclerosis  
200 or neuromyelitis optica. *Mult Scler J*. 2022; doi: 10.1177/ 13524585211049737.
- 201 8. Sormani MP, Schiavetti I, Carmisciano L et al. COVID-19 Severity in Multiple Sclerosis: Putting  
202 Data Into Context. *Neurol Neuroimmunol Neuroinflamm*. 2021 Nov 9;9(1):e1105. doi:  
203 10.1212/NXI.0000000000001105. Print 2022 Jan.
- 204 9. Sormani MP, Schiavetti I, Inglese M et al. Breakthrough SARS-CoV-2 infections after COVID-19  
205 mRNA vaccination in MS patients on disease modifying therapies. . medRxiv 2021.12.23.21268177;  
206 doi: <https://doi.org/10.1101/2021.12.23.21268177>.



- 208 10. Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and Coronavirus Disease  
209 2019 Severity in Multiple Sclerosis. *Ann Neurol*. 2021;89(4):780-789. Doi:10.1002/ana.26028  
210 11. Brown, Lawrence D.; Cai, T. Tony; DasGupta, Anirban (2001). "Interval Estimation for a Binomial  
211 Proportion". *Statistical Science*. 16 (2): 101–133.

212

## 213 **Acknowledgements**

214 Supported by FISM [2021/Special-Multi/001]

215

## 216 **Disclosures**

217 Annovazzi received honoraria for lecturing and participation in advisory boards, and/or travel expenses for  
218 attending congresses and meetings from Almirall, Biogen, BMS-Celgene, Merck, Novartis, Roche, Sanofi-  
219 Genzyme, Teva Italia, and Viatrix.

220 Bonavita received speaker and/or advisors board fee from Biogen, Novartis, Roche, viatrix, Merck serono.

221 Caleri received honoraria for advisory board and/or for public speaking, and/or travel grant, from Biogen,  
222 Merck, Teva, Novartis, Sanofi-Genzyme, Roche.

223 Cavalla has received advisory board membership, speaker honoraria or travel grants to attend national and  
224 international conferences from Biogen, Merck-Serono, Teva, Roche, Novartis, Cellgene-BMS and Sanofi-  
225 Genzyme.

226 Clerico received grants and consulting fees from Merck, Biogen, Novartis, Sanofi-Genzyme, Roche,  
227 Almirall.

228 Cola, Pasquali, Cocco, Ferrò, Liberatore, Rilla, Stromillo have nothing to disclose.

229 Conte reports speaking honoraria from Merck, Sanofi, Novartis, Biogen, Roche, Bristol Myers Squibb,  
230 Almirall and has received research support from Roche, Biogen and Merck.

231 Cordioli received personal compensation for advisory board and speaking for Merck Serono, Novartis,  
232 Almirall, Biogen and Roche.

233 Di Filippo participated on advisory boards for and received research support, speaker/writing honoraria and  
234 funding for traveling from Bayer, Biogen Idec, Genzyme, Merck, Mylan, Novartis, Roche, Teva and Viatrix

235 Di Sapio received personal compensation for speaking and consulting by Biogen, Novartis and Genzyme and  
236 has been reimbursed by Merck, Biogen, Genzyme and Roche for attending several conferences.

237 Docimo received grants from Roche, Novartis, Biogen, Merck, Viatrix, Genzyme.

238 Ferraro received travel grants and/or speaker/advisory board honoraria from Biogen, Roche, Novartis,  
239 TEVA, Sanofi Genzyme, Merck Serono.

240 Immovilli reports personal fees from Roche, Biogen, Merck.

241 Iodice received speaker honoraria and/or consultancy from Biogen, Teva, Genzyme, Merck, Almirall,  
242 Roche.

- 243 Lanzillo received personal compensations for speaking or consultancy from Biogen, Teva, Genzyme, Merck,  
244 Mylan, Novartis and Roche.
- 245 Laroni received personal compensations from Merck, Biogen, Novartis, Roche, Almirall.
- 246 Patti received personal compensation for serving on advisory board Almirall, Bayer, Biogen, Bristol Meyers  
247 Squibb, Merck, Novartis, Roche and Sanofi; he further received unrestricted research grants by Biogen,  
248 Merck, Roche, FISM, University of Catania and Reload (onlus patients association).
- 249 Ruscica received speaker and/or advisors board fee from Merck, Novartis, Biogen, Genzyme.
- 250 Salvetti reports grants and personal fees from Biogen, Merck, Novartis, Roche, Sanofi, Teva, grants from  
251 Italian Multiple Sclerosis Foundation, grants from Sapienza University of Rome.
- 252 Schiavetti received consulting fees from Hippocrates Research, NovaNeuro, Sakura Italia, ADL  
253 Farmaceutici, Associazione Commissione Difesa Vista Onlus.
- 254 Signoriello received speaker honoraria and/or consultancy from Biogen, Teva, Genzyme, Merck, Novartis,  
255 Almirall, Roche.
- 256 Sormani received consulting fees from Merck, Biogen, Novartis, Sanofi, Roche, Geneuro, GSK, Medday,  
257 Immunic.
- 258 Ulivelli received consulting fees from Biogen, Novartis, Serono.

**Table 1: Characteristics of patients with breakthrough infections (N = 137)**

<b>Female sex</b>		85 (62.0)
<b>Age, years</b>		42.3 ± 10.70
<b>BMI (kg/m<sup>2</sup>)</b>		24.6 ± 4.95
<b>MS phenotype</b>	Primary progressive	9 (6.6)
	Relapsing remitting	116 (84.7)
	Secondary progressive	7 (5.1)
	Missing data	5 (3.6)
<b>Disease duration, months</b>		99.5 (44.0 - 182.0)
<b>Last EDSS before Covid-19 infection</b>		2.0 (1.0 - 3.5)
<b>Relapse in the six months before Covid-19 infection</b>		7 (5.1)
<b>Number of breakthrough infections in each DMT/number of vaccinated patients, (%)</b>	alemtuzumab	0/371 (0.0)
	azathioprine	0/298 (0.0)
	cladribine	4/570 (0.70)
	dimethyl fumarate	22/2668 (0.82)
	fingolimod	28/1733 (1.61)
	glatiramer acetate	4/1514 (0.26)
	interferon	7/2452 (0.29)
	natalizumab	15/1843 (0.81)
	ocrelizumab	36/1794 (2.00)
	rituximab	3/364 (0.82)
	teriflunomide	10/1379 (0.73)
	other	0/389 (0.0)
	untreated	8/4266 (0.19)
<b>Boost COVID-19 vaccination</b>		26 (19.0)
<b>Heterologous vaccine</b>		4 (2.9)
<b>Covid severity</b>	Asymptomatic, viral RNA detected	16 (11.8)
	Symptomatic, independent	95 (69.3)
	Symptomatic, assistance needed	16 (11.8)
	Hospitalized, no oxygen therapy	4 (2.9)
	Oxygen by mask or nasal prongs	5 (3.7)
	Intubation and mechanical ventilation, piO <sub>2</sub> /FiO <sub>2</sub> ≥150 or SpO <sub>2</sub> /FiO <sub>2</sub> ≥200	1 (0.7)

*Results are expressed as count (%), mean ± Standard Deviation, or median [Inter Quartile Range], as appropriate.*

*MS=Multiple Sclerosis, BMI=Body Mass Index, EDSS=Expanded Disability Status Scale, DMT=Disease Modifying Therapy*

261 **Breakthrough infections in MS study group**

262

<b>Name Surname</b>	<b>Affiliation</b>
Agostino Giulio <b>Lanuto</b>	Federico II university of Naples
Alessandro <b>Giannotta</b>	Department of Medical Sciences, Surgery and Neurosciences, University of Siena
Alessia <b>Di Sapia</b>	Department of Neurology, Regina Montis Regalis Hospital, Mondovì, Italy
Alice <b>Laroni</b>	1 - Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Italy AND IRCCS Ospedale Policlinico San Martino, Genova, Italy 2 - IRCCS Ospedale Policlinico San Martino, Genova, Italy
Anastasia <b>Alteno</b>	Multiple Sclerosis Center, Department of Neuroscience, City of Health and Science University Hospital of Turin, Italy
Antonella <b>Conte</b>	1- Department of Human Neuroscience, Sapienza, University of Rome, Italy. 2- IRCCS Neuromed, Pozzilli (IS), Italy
Carlo <b>Serrati</b>	Ospedale Civile Imperia
Caterina <b>Lapucci</b>	IRCCS Ospedale Policlinico San Martino, Genova, Italy
Chiara Rosa <b>Mancinelli</b>	Centro Sclerosi Multipla ASST Spedali Civili di Brescia
Cinzia <b>Cordioli</b>	Centro Sclerosi Multipla ASST Spedali Civili di Brescia
Clara Grazia <b>Chisari</b>	Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, Catania, Italy.
Daiana <b>Bezzini</b>	Department of Life Sciences, University of Siena
Damiano <b>Baroncini</b>	UOC Centro Sclerosi Multipla, ASST Valle-Olona, PO di Gallarate (VA)
Diana <b>Ferraro</b>	Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy
Donata <b>Guidetti</b>	Guglielmo da Saliceto Hospital, Piacenza
Doriana <b>Landi</b>	Department of Systems Medicine, Multiple Sclerosis Clinical and Research Unit, Tor Vergata University, Rome, Italy
Eduardo <b>Nobile-Orazio</b>	1. Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy 2. Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy
Elena <b>Di Sabatino</b>	Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy
Eleonora <b>Cocco</b>	Centro Sclerosi Multipla Ospedale Binaghi Cagliari
Elisabetta <b>Signoriello</b>	II Division of Neurology, University of Campania Luigi Vanvitelli
Elvira <b>Sbragia</b>	Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Italy AND IRCCS Ospedale Policlinico San

	Martino, Genova, Italy
<b>Emanuele Cassano</b>	Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy.
<b>Enri Nako</b>	Department of Neurology, Regina Montis Regalis Hospital, Mondovì, Italy
<b>Fabio Della Cava</b>	Ospedale Civile Imperia
<b>Flora Govone</b>	Department of Neurology, Regina Montis Regalis Hospital, Mondovì, Italy
<b>Francesca Bianchi</b>	Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa, Italy
<b>Francesca Caleri</b>	Department of Neurology, MS Center, F. Tappeiner Hospital Meran (BZ), Italy
<b>Francesca Ruscica</b>	U.O.C. Neurologia e Centro SM - Fondazione Istituto G. Giglio, Cefalù (Italy)
<b>Francesca Vitetta</b>	Neurology Unit, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
<b>Francesco Patti</b>	Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, Catania, Italy.
<b>Gabriele Siciliano</b>	Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa, Italy
<b>Gaia Cola</b>	Department of Systems Medicine, Multiple Sclerosis Clinical and Research Unit, Tor Vergata University, Rome, Italy
<b>Giacomo Lus</b>	II Division of Neurology, University of Campania Luigi Vanvitelli
<b>Gianmarco Abbadessa</b>	Dipartimento di Scienze Mediche e Chirurgiche avanzate, Università della Campania Luigi Vanvitelli, Naples-Italy
<b>Gianmarco Bellucci</b>	Department of Neuroscience, Mental Health and Sensory Organs Sapienza University, S. Andrea Hospital, Rome
<b>Girolama Alessandra Marfia</b>	Department of Systems Medicine, Multiple Sclerosis Clinical and Research Unit, Tor Vergata University, Rome, Italy
<b>Giuditta Ilaria Scarano</b>	Department of Psychology, F. Tappeiner Hospital Meran (BZ), Italy
<b>Giuseppe Liberatore</b>	Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
<b>Giuseppina Miele</b>	Dipartimento di Scienze Mediche e Chirurgiche avanzate, Università della Campania Luigi Vanvitelli, Naples-Italy
<b>Graziella Callari</b>	U.O.C. Neurologia e Centro SM - Fondazione Istituto G. Giglio, Cefalù (Italy)
<b>Guido Urbano</b>	Dipartimento di Neuroscienze "Rita Levi Montalcini, Università di Torino
<b>Irene Schiavetti</b>	Department of Health Sciences, Section of Biostatistics, University of Genova, Italy
<b>Jessica Frau</b>	Centro Sclerosi Multipla Ospedale Binaghi Cagliari
<b>Leonardo Malimpensa</b>	Department of Human Neuroscience, Sapienza, University of Rome, Italy
<b>Lia Allegorico</b>	Nola Hospital "Santa Maria della Pietà", ASL Napoli 3 Sud, Nola (Na) Italy
<b>Livia Pasquali</b>	Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa, Italy

<b>Lorena Lorefice</b>	Centro Sclerosi Multipla Ospedale Binaghi Cagliari
<b>Lorenzo Gaetani</b>	Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy
<b>Lucia Ruggiero</b>	Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy
<b>Marco Salvetti</b>	Department of Neuroscience, Mental Health and Sensory Organs. Sapienza University, S. Andrea Hospital, Rome
<b>Marco Vercellino</b>	Multiple Sclerosis Center and 1st Division of Neurology, Department of Neuroscience, City of Health and Science University Hospital of Turin, Italy
<b>Maria Chiara Buscarinu</b>	Department of Neuroscience, Mental Health and Sensory Organs Sapienza University, S. Andrea Hospital, Rome
<b>Maria Francesca Creta</b>	1. Neuromuscular and Neuroimmunology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy 2. Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy
<b>Maria Laura Stromillo</b>	Clinica Neurologica e Malattie Neurometaboliche, Università degli Studi di Siena
<b>Maria Pia Sormani</b>	1- Department of Health Sciences, Section of Biostatistics, University of Genova, Italy 2- IRCCS Ospedale Policlinico San Martino, Genova, Italy
<b>Maria Rosaria Pennacchio</b>	Multiple Sclerosis Center, Aversa Hospital "San Giuseppe Moscati", ASL Caserta, Aversa (Ce) Italy
<b>Maria Teresa Ferrò</b>	Neuroimmunology, Center for Multiple Sclerosis, Cardiocerebrovascular Department, Neurological Unit, ASST Crema
<b>Maria Teresa Rilla</b>	Ospedale Civile Imperia
<b>Marinella Clerico</b>	Dipartimento di Scienze Cliniche e Biologiche, Università di Torino
<b>Massimiliano Di Filippo</b>	Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy
<b>Matteo Scialabba</b>	U.O.C. Neurologia e Centro SM - Fondazione Istituto G. Giglio, Cefalù (Italy)
<b>Mauro Zaffaroni</b>	UOC Centro Sclerosi Multipla, ASST Valle-Olona, PO di Gallarate (VA)
<b>Monica Ulivelli</b>	Department of Medical Sciences, Surgery and Neurosciences, University of Siena
<b>Nicola De Stefano</b>	Clinica Neurologica e Malattie Neurometaboliche, Università degli Studi di Siena
<b>Paola Cavalla</b>	Multiple Sclerosis Center and 1st Division of Neurology, Department of Neuroscience, City of Health and Science University Hospital of Turin, Italy
<b>Paola De Mitri</b>	Guglielmo da Saliceto Hospital, Piacenza
<b>Paolo Immovilli</b>	Guglielmo da Saliceto Hospital, Piacenza
<b>Patrizia Sola</b>	Neurology Unit, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy
<b>Pietro Annovazzi</b>	UOC Centro Sclerosi Multipla, ASST Valle-Olona, PO di Gallarate (VA)
<b>Raffaele Nardone</b>	1. Paracelsus Medical University, Department of Neurology, Salzburg-AU 2. Department of Neurology, F. Tappeiner Hospital Meran (BZ), Italy

Renato <b>Docimo</b>	Multiple Sclerosis Center, Aversa Hospital "San Giuseppe Moscati", ASL Caserta, Aversa (Ce) Italy
Roberta <b>Lanzillo</b>	Federico II university of Naples
Rosa <b>Iodice</b>	Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy
Rosanna <b>Missione</b>	II Division of Neurology, University of Campania Luigi Vanvitelli
Sarah <b>Rasia</b>	Centro Sclerosi Multipla ASST Spedali Civili di Brescia
Sebastiano <b>Arena</b>	Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, Catania, Italy.
Simona <b>Bonavita</b>	Dipartimento di Scienze Mediche e Chirurgiche avanzate, Università della Campania Luigi Vanvitelli, Naples-Italy
Simona <b>Rolla</b>	Dipartimento di Scienze Cliniche e Biologiche, Università di Torino
Vincenzo <b>Brescia Morra</b>	Federico II University of Naples
Viola <b>Baione</b>	Department of Human Neuroscience, Sapienza, University of Rome, Italy.

263

264

265

266



267 **Figure legends**

268 **Figure 1. Cumulative incidence of breakthrough infections in patients in each DMT group (A)**

269 **and breakthrough infection rates according to time since vaccination in ocrelizumab,**

270 **fingolimod and other DMTs (B).**

271



*\*Ocrelizumab and fingolimod had a percentage of breakthrough infections that is significantly higher ( $p < 0.001$ ) than the percentage in all the other DMT groups.*